Saturday 17 October 2026
Export DARE’s income statement to Excel — free account
Dare Bioscience, Inc.
DARE Healthcare Biotechnology
Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024. In the quarter to June 2026, revenue grew 984.4%, EPS grew 55.6% and free cash flow fell 30.2%, each against the same quarter a year earlier.
0.72
0.02
−2.70%
Follow DARE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
23.00 | 22.84 | 20.94 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.64) | (4.79) | 14.94 | (60.59) | |
P/B ratio |
0.00 | 36.02 | 7.59 | 9.37 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
19.88 | 14.06 | 5.07 | (211.34) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.40) | (1.64) | (0.53) | (2.00) | |
EV/FCF |
(2.34) | (1.58) | (0.51) | (1.78) | |
Quick Ratio |
0.77 | 0.91 | 1.07 | 1.11 | |
Current Ratio |
0.99 | 1.03 | 1.14 | 1.18 | |
Net Debt/EBITDA |
5.27 | 7.58 | 23.04 | 7.47 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.54% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.06 | |
Asset Turnover |
0.08 | 0.05 | 0.04 | 0.00 | |
Operating CF/Net income |
2.27 | 1.84 | (1.00) | 0.12 | |
Capex/Depreciation |
(0.14) | 0.00 | (0.52) | (0.29) | |
Research and Development Expense of Revenue |
129.07% | 433.11% | 60.76% | 51,095.65% | |
Selling, General and Administrative Expense of Revenue |
1,383.31% | 1,474.49% | 154.06% | 108,660.87% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
152.85% | 298.43% | 34.89% | 17,521.74% | |
Graham Net Nets |
(0.20) | (0.21) | (0.12) | (0.11) | |
Graham Number |
0.77 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(33.18%) | (52.20%) | (64.77%) | (89.05%) | |
Free Cash Flow Yield |
(36.93%) | (39.05%) | (47.61%) | (25.26%) | |
Revenue per Share |
0.01 | 0.01 | 0.09 | 0.00 | |
Operating CF per Share |
(0.45) | (0.38) | 0.13 | (0.03) | |
Capex per Share |
(0.01) | 0.00 | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.46) | (0.38) | 0.11 | (0.05) | |
Cash per Share |
0.85 | 1.28 | 2.21 | 1.81 | |
Shareholders Equity per Share |
(0.04) | 0.05 | 0.25 | 0.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.04) | 0.05 | 0.25 | 0.22 | |
Free Cash Flow |
(6.86) | (5.52) | 1.24 | (0.62) | |
Working Capital |
(0.24) | 0.54 | 3.38 | 3.79 | |
Capital Expenditures |
(0.08) | — | (0.21) | (0.17) | |
Net Current Asset Value |
(6.24) | (5.43) | (2.57) | (2.89) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.43 | 0.00 | 0.20 | 75.96 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.32 | 0.40 | 0.40 | 0.44 | |
Average Payables |
1.26 | 1.56 | 1.33 | 1.45 | |
Average Assets |
17.67 | 23.22 | 27.29 | 24.40 | |
Average Common Equity |
(6.65) | (4.41) | (1.58) | 0.69 |
Columns are period end dates